-
Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $1.99
-
Calidi Biotherapeutics receives FDA fast track designation for CLD-201
-
Calidi Biotherapeutics (CLDI) announces 1:12 reverse share split
-
Calidi Biotherapeutics raises $4.6 million through warrant exercise
-
Calidi Biotherapeutics (CLDI) Misses Q1 EPS by 18c
-
Calidi Biotherapeutics (CLDI) Announces CEO Change
-
Calidi Biotherapeutics (CLDI) Announces Proposed Public Offering
-
Calidi Biotherapeutics, Inc. (CLDI) Misses Q3 EPS by 46c
-
Calidi Biotherapeutics (CLDI) Announces Proposed Public Offering
-
Calidi Biotherapeutics (CLDI) Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
-
Calidi Biotherapeutics (CLDI) Halted, News Pending
-
Calidi Biotherapeutics (CLDI) Files $25M Mixed Shelf
-
Calidi Biotherapeutics Inc (CLDI) PT Lowered to $2.50 at Baird
-
Calidi Biotherapeutics, Inc. (CLDI) Misses Q2 EPS by 121c
-
Calidi Biotherapeutics (CLDI) Announces 1:10 Reverse Share Split
-
Calidi Biotherapeutics (CLDI) Appoints George Peoples to its Board

